TGX-007 + valaciclovir

TGX-007 + valaciclovir is an investigational combination therapy being developed by Trogenix for the treatment of newly diagnosed and recurrent glioblastoma and other high-grade gliomas. TGX-007 is a dual-payload adeno-associated virus (AAV) vector administered via a single intratumoral injection. It utilizes Trogenix's proprietary Synthetic Super-Enhancer (SSE) technology to selectively drive expression of its payloads within tumor cells by targeting the core SOX2 and SOX9 transcriptional circuitry. The first payload is herpes simplex virus thymidine kinase (HSV-tk), which converts orally administered valaciclovir (a small-molecule nucleoside analogue prodrug) into a cytotoxic active metabolite that selectively kills proliferating tumor cells. The second payload is interleukin-12 (IL-12), which stimulates a localized anti-tumor immune response. Together, this dual mechanism acts as an in-situ cancer vaccine to promote long-lasting immunological memory. The combination is currently being evaluated in the Phase I/II ADePT clinical trial (NCT07346144).